Literature DB >> 29236171

Uterine fibroid size modifications during pregnancy and puerperium: evidence from the first systematic review of literature.

Amerigo Vitagliano1, Marco Noventa2, Attilio Di Spiezio Sardo3, Gabriele Saccone3, Salvatore Gizzo2, Shara Borgato2, Salvatore Giovannni Vitale4, Antonio Simone Laganà4, Giovanni Battista Nardelli2, Pietro Salvatore Litta2, Carlo Saccardi2.   

Abstract

PURPOSE: The influence of pregnancy on uterine fibroid size still remains an unsolved dilemma. Basing on current knowledge, physicians are not able to inform patients about the likelihood of uterine fibroids to modify their size during pregnancy. Study aim was to summarize available evidence concerning the size modifications of uterine fibroids during each trimester of pregnancy and during puerperium.
METHODS: The review was reported following the PRISMA guidelines and registered in PROSPERO (registration number: CRD42017071117). A literature search was conducted in electronic database (PubMed, Embase, Sciencedirect, the Cochrane library and Clinicaltrials.gov) until July 2017. All studies evaluating fibroids' changes during pregnancy and puerperium by ultrasound or magnetic-resonance-imaging were included. Descriptive characteristics of studies and patients were collected. The modifications of uterine fibroid diameter and volume were the outcome measures.
RESULTS: Concerning the first trimester of pregnancy, all authors reported a significant growth of uterine fibroids. Contradictory evidence was found about uterine fibroid modifications during the second and third trimesters, mainly supporting a slowdown during mid pregnancy and a subsequent size reduction during late pregnancy. Concerning the overall modifications during pregnancy and puerperium, poor evidence quality suggests that uterine fibroids do not modify their volume/slightly enlarge during pregnancy and subsequently reduce in size during puerperium.
CONCLUSIONS: Uterine fibroids seem to be subject to a non-linear trend of modifications during pregnancy and puerperium, which may vary from myoma to myoma. Adequate evidence supports uterine fibroid systematic enlargement during the first trimester of pregnancy, while inconsistent evidence is available about the changes of uterine fibroids during second and third trimesters. In addition, the overall modifications of myomas during pregnancy and puerperium remain unclear.

Entities:  

Keywords:  Fibroid size; Pregnancy; Puerperium; Size modifications; Uterine fibroids

Mesh:

Year:  2017        PMID: 29236171     DOI: 10.1007/s00404-017-4621-4

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  19 in total

1.  Effect of pregnancy on recurrence of symptomatic uterine myomas in women who underwent myomectomy.

Authors:  R T Aksoy; A Tokmak; A I Guzel; G Yildirim; M K Kokanali; M Doganay
Journal:  Hippokratia       Date:  2018 Jul-Sep       Impact factor: 0.471

Review 2.  Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids.

Authors:  Mohamed Ali; Mohamed Raslan; Michał Ciebiera; Kornelia Zaręba; Ayman Al-Hendy
Journal:  Expert Opin Drug Saf       Date:  2021-10-20       Impact factor: 4.250

3.  Natural history of fibroids in pregnancy: National Institute of Child Health and Human Development Fetal Growth Studies - Singletons cohort.

Authors:  Susanna D Mitro; Shyamal Peddada; Zhen Chen; Germaine M Buck Louis; Jessica L Gleason; Cuilin Zhang; Katherine L Grantz
Journal:  Fertil Steril       Date:  2022-08-16       Impact factor: 7.490

Review 4.  Review of uterine fibroids: imaging of typical and atypical features, variants, and mimics with emphasis on workup and FIGO classification.

Authors:  Muhammad O Awiwi; Mohamed Badawy; Akram M Shaaban; Christine O Menias; Jeanne M Horowitz; Moataz Soliman; Corey T Jensen; Ayman H Gaballah; Juan J Ibarra-Rovira; Myra K Feldman; Mindy X Wang; Peter S Liu; Khaled M Elsayes
Journal:  Abdom Radiol (NY)       Date:  2022-05-13

5.  Spontaneous complete regression of large uterine fibroid after the second vaginal delivery: Case report.

Authors:  Myounghwan Kim
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

6.  Isoliquiritigenin Suppresses E2-Induced Uterine Leiomyoma Growth through the Modulation of Cell Death Program and the Repression of ECM Accumulation.

Authors:  Po-Han Lin; Hsiang-Lin Kung; Hsin-Yuan Chen; Ko-Chieh Huang; Shih-Min Hsia
Journal:  Cancers (Basel)       Date:  2019-08-07       Impact factor: 6.639

7.  Growth pattern of uterine leiomyoma along pregnancy.

Authors:  Henry Hillel Chill; Gilad Karavani; Talya Rachmani; Uri Dior; Ofer Tadmor; Asher Shushan
Journal:  BMC Womens Health       Date:  2019-07-22       Impact factor: 2.809

Review 8.  The Role of miRNA and Related Pathways in Pathophysiology of Uterine Fibroids-From Bench to Bedside.

Authors:  Michał Ciebiera; Marta Włodarczyk; Stanisław Zgliczyński; Tomasz Łoziński; Klaudia Walczak; Artur Czekierdowski
Journal:  Int J Mol Sci       Date:  2020-04-24       Impact factor: 5.923

Review 9.  Uterine Fibroids and Pregnancy: How Do They Affect Each Other?

Authors:  Larissa M Coutinho; Wiviane A Assis; Ananda Spagnuolo-Souza; Fernando M Reis
Journal:  Reprod Sci       Date:  2021-06-17       Impact factor: 2.924

10.  5-aza-2'-deoxycitidine inhibits cell proliferation, extracellular matrix formation and Wnt/β-catenin pathway in human uterine leiomyomas.

Authors:  Irene Cervelló; Hortensia Ferrero; María Cristina Carbajo-García; Ana Corachán; Marina Segura-Benitez; Javier Monleón; Julia Escrig; Amparo Faus; Antonio Pellicer
Journal:  Reprod Biol Endocrinol       Date:  2021-07-08       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.